RenovoRx, Inc.
(NASDAQ:RNXT) announced Tuesday that it has completed patient enrollment for its Phase 3 TIGeR-PaC study of its targeted drug delivery platform for locally advanced pancreatic cancer (LAPC).
The U.S.
Food and Drug Administration (FDA)-cleared RenovoCath to isolate blood flow and deliver fluids within the peripheral vascular system, as well as for temporary vessel occlusion during procedures such as chemotherapeutic drug infusion.
RenovoRx is evaluating its novel drug-device combination oncology product candidate, intra-arterial gemcitabine delivered via RenovoCath (known as IAG), in the ongoing Phase 3 TIGeR-PaC trial.
